Janux Q3 net loss $16.7M; first patient dosed in JANX007 Phase 1 trial

Janux Therapeutics, Inc.

2022-Q3 EPS reported -$1.13 revenue$5,767,000

Q3 2022 net loss of $16.7M vs $10.8M prior year; R&D spend $13.7M (up from $8.4M).
Cash and short-term investments $338.8M at Sep 30, 2022, down from $375.0M at Dec 31, 2021.
First patient dosed with JANX007 in Phase 1 trial for prostate cancer; interim data expected 2H 2023.
IND for EGFR-TRACTr (JANX008) on track for 2H 2022; PD-L1xCD28 TRACIr (JANX009) IND planned for 2023.
Strengthened management with new HR head and board addition Winston Kung.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Janux Therapeutics, Inc. reported financial results for the three and nine months ended September 30, 2022.

Period: the three and nine months ended September 30, 2022
Result: reported results

Exact text from the filing

On November 10, 2022, Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Janux Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-024472

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.